e-ISSN: Pending
Negative / Null Result ReportOpen accessDiseases of the musculoskeletal system

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Talia Golan; Ravit Geva; Donald Richards; Srinivasan Madhusudan; Boris Kin Lin; Haofei Tiffany Wang; Richard A. Walgren; Salomon M. Stemmer · 2018 · Journal of Cachexia, Sarcopenia and Muscle

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Background Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier. Methods In this randomized, phase 2 trial, patients with stage II–IV pancreatic cancer were randomized to 300 mg LY2495655, 100 mg LY2495655, or placebo, plus physician‐choice chemotherapy from a prespecified list of standard‐of‐care regimens for first and later lines of care. Investigational treatment was continued during second‐line treatment. The primary endpoint was

Abstract by Talia Golan; Ravit Geva; Donald Richards; Srinivasan Madhusudan; Boris Kin Lin; Haofei Tiffany Wang; Richard A. Walgren; Salomon M. Stemmer, Journal of Cachexia, Sarcopenia and Muscle (2018) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1002/jcsm.12331